P
HZNP

Pitcairn’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Pitcairn’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,669
Closed -$1M – 706
2023
Q3 		$1M Buy
8,669
+718
+9% +$77.1K 0.08% 209
2023
Q2 		$818K Sell
7,951
-68
-0.8% -$7.17K 0.07% 241
2023
Q1 		$875K Sell
8,019
-10,598
-57% -$1.17M 0.08% 221
2022
Q4 		$2.12M Sell
18,617
-88
-0.5% -$7.31K 0.21% 95
2022
Q3 		$1.16M Sell
18,705
-47
-0.3% -$3.28K 0.13% 154
2022
Q2 		$1.5M Buy
18,752
+9
+0% +$852 0.16% 118
2022
Q1 		$1.97M Buy
18,743
+98
+0.5% +$9.55K 0.17% 106
2021
Q4 		$2.01M Sell
18,645
-409
-2% -$44.6K 0.13% 114
2021
Q3 		$2.09M Sell
19,054
-198
-1% -$20.6K 0.14% 100
2021
Q2 		$1.8M Sell
19,252
-499
-3% -$45.9K 0.12% 120
2021
Q1 		$1.82M Buy
19,751
+5,774
+41% +$487K 0.13% 115
2020
Q4 		$1.02M Buy
13,977
+102
+0.7% +$7.58K 0.08% 173
2020
Q3 		$1.08M Sell
13,875
-1,169
-8% -$80.4K 0.09% 140
2020
Q2 		$837K Sell
15,044
-1,124
-7% -$48.1K 0.08% 152
2020
Q1 		$479K Buy
16,168
+1,344
+9% +$45.5K 0.06% 207
2019
Q4 		$536K Sell
14,824
-322
-2% -$9.87K 0.05% 245
2019
Q3 		$412K Sell
15,146
-1,043
-6% -$27K 0.04% 280
2019
Q2 		$390K Buy
16,189
+22
+0.1% +$558 0.04% 298
2019
Q1 		$427K Buy
+16,167
New +$383K 0.05% 256
2018
Q4 		– Sell
-14,915
Closed -$292K – 563
2018
Q3 		$292K Buy
+14,915
New +$284K 0.03% 410

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pitcairn's HZNP Position: Q4 2023 in Review

Pitcairn sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 8,669 shares — an estimated $1M sold.

Pitcairn first reported a position in HZNP in Q3 2018 and held it in 20 quarters. The position peaked at $2.12M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Pitcairn reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Pitcairn sold 8,669 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1M.
  • Pitcairn first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 20 quarters.
  • Pitcairn's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.12M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Pitcairn's 13F filing for Q4 2023, filed 14 Feb 2024.